Tenderwize
Wróć do wyszukiwania

Non-exclusive Drug Discount Agreement for Nilotinib

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jul 31, 2027 · 338 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Nilotinib (ATC-Code nach WHO: L01EA03)

50/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

50 / 100

Złożoność

20 / 100

Czynniki ryzyka

No minimum purchase guarantees; actual demand depends on prescription behavior and may be low.

The buyer may terminate the procedure early if exclusive agreements are concluded, ending all non-exclusive agreements.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Supply of pharmaceutical products containing Nilotinib (ATC L01EA03) to AOK PLUS insured members in Saxony and Thuringia
  • Non-exclusive discount agreement under §130a Abs. 8 SGB V
Pokaż pełne podsumowanie

This tender is a non-exclusive drug discount agreement (Rabattvereinbarung) under §130a Abs. 8 SGB V for the active substance Nilotinib (ATC L01EA03), conducted as an Open-House model by AOK PLUS for Saxony and Thuringia. The procedure is voluntary transparency publication, not a formal procurement under EU directive. Any qualified pharmaceutical entrepreneur can join during the participation period. No guaranteed volumes, no exclusivity, and the agreement ends by 31 July 2027 unless terminated earlier due to exclusive agreements. The estimated value is not disclosed. Submission is electronic via DTVP portal; first deadline 7 July 2026, with subsequent periodic deadlines.

Ryzyka

No minimum purchase guarantees; actual demand depends on prescription behavior and may be low.

The buyer may terminate the procedure early if exclusive agreements are concluded, ending all non-exclusive agreements.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG with respect to the offered medicines

Eligibility

  • Must submit a self-declaration on exclusion grounds (Eigenerklärung zum Nichtvorliegen von Ausschlussgründen)

Administrative

  • Must submit a self-declaration on Russia sanctions (Eigenerklärung Russlandsanktionen)

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

Price: The discount is the key criterion but not formally weighted; acceptance is based on meeting participation requirements and accepting the terms.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive Drug Discount Agreement for Nilotinib

Open-House model for concluding non-exclusive rebate agreements for Nilotinib (excluding Nilotinib dispersed in applesauce unless patent-protected). The agreement is open to all interested pharmaceutical entrepreneurs meeting the requirements. No minimum purchase quantities, no exclusivity. Contract ends by 31 July 2027.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Jul 2026 - Jul 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

Price

Termin

Deadline Jul 31, 2027

Szczegóły zamówienia

Data publikacji
05 May 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
308469-2026

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3